Her2-Negative Metastatic Breast Cancer

SAN ANTONIO — In this video, Halle Moore, MD, discusses the long-term results of the OlympiA trial presented at San Antonio Breast Cancer Symposium.

The FDA approved capivasertib as part of combination therapy for certain patients with hormone receptor-positive, HER2-negative locally advanced or metastatic breast cancer.

The FDA granted fast track designation to gedatolisib for treatment of certain patients with breast cancer.